Imagion Biosystems gives notice that, on 4 September 2020 the Company issued 2,514,666 fully paid ordinary shares (Shares) in the Company as the result of shareholders exercising their options in the Company.
Read the notice.
Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update
July 15, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging